294 related articles for article (PubMed ID: 28403145)
21. Monoterpenoid-based inhibitors of filoviruses targeting the glycoprotein-mediated entry process.
Sokolova AS; Yarovaya OI; Zybkina AV; Mordvinova ED; Shcherbakova NS; Zaykovskaya AV; Baev DS; Tolstikova TG; Shcherbakov DN; Pyankov OV; Maksyutov RA; Salakhutdinov NF
Eur J Med Chem; 2020 Dec; 207():112726. PubMed ID: 32905862
[TBL] [Abstract][Full Text] [Related]
22. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.
Johansen LM; Brannan JM; Delos SE; Shoemaker CJ; Stossel A; Lear C; Hoffstrom BG; Dewald LE; Schornberg KL; Scully C; Lehár J; Hensley LE; White JM; Olinger GG
Sci Transl Med; 2013 Jun; 5(190):190ra79. PubMed ID: 23785035
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection.
Zhang X; Ao Z; Bello A; Ran X; Liu S; Wigle J; Kobinger G; Yao X
Antiviral Res; 2016 Mar; 127():20-31. PubMed ID: 26778707
[TBL] [Abstract][Full Text] [Related]
24. Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry.
Qiu S; Leung A; Bo Y; Kozak RA; Anand SP; Warkentin C; Salambanga FDR; Cui J; Kobinger G; Kobasa D; Côté M
Virology; 2018 Jan; 513():17-28. PubMed ID: 29031163
[TBL] [Abstract][Full Text] [Related]
25. Filoviruses Use the HOPS Complex and UVRAG To Traffic to Niemann-Pick C1 Compartments during Viral Entry.
Bo Y; Qiu S; Mulloy RP; Côté M
J Virol; 2020 Jul; 94(16):. PubMed ID: 32493822
[TBL] [Abstract][Full Text] [Related]
26. Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo.
Pessi A; Bixler SL; Soloveva V; Radoshitzky S; Retterer C; Kenny T; Zamani R; Gomba G; Gharabeih D; Wells J; Wetzel KS; Warren TK; Donnelly G; Van Tongeren SA; Steffens J; Duplantier AJ; Kane CD; Vicat P; Couturier V; Kester KE; Shiver J; Carter K; Bavari S
Antiviral Res; 2019 Nov; 171():104592. PubMed ID: 31473342
[TBL] [Abstract][Full Text] [Related]
27. Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by
Mittler E; Alkutkar T; Jangra RK; Chandran K
mBio; 2021 Jan; 12(1):. PubMed ID: 33436438
[TBL] [Abstract][Full Text] [Related]
28. Pharmacologically induced endolysosomal cholesterol imbalance through clinically licensed drugs itraconazole and fluoxetine impairs Ebola virus infection
Kummer S; Lander A; Goretzko J; Kirchoff N; Rescher U; Schloer S
Emerg Microbes Infect; 2022 Dec; 11(1):195-207. PubMed ID: 34919035
[TBL] [Abstract][Full Text] [Related]
29. Ebola Virus Uptake into Polarized Cells from the Apical Surface.
Hu M; Wang F; Li W; Zhang X; Zhang Z; Zhang XE; Cui Z
Viruses; 2019 Dec; 11(12):. PubMed ID: 31810353
[TBL] [Abstract][Full Text] [Related]
30. The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.
Baranov MV; Bianchi F; van den Bogaart G
Cells; 2020 Dec; 10(1):. PubMed ID: 33375410
[TBL] [Abstract][Full Text] [Related]
31. Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action.
Selaković Ž; Tran JP; Kota KP; Lazić M; Retterer C; Besch R; Panchal RG; Soloveva V; Sean VA; Jay WB; Pavić A; Verbić T; Vasiljević B; Kuehl K; Duplantier AJ; Bavari S; Mudhasani R; Šolaja BA
Eur J Med Chem; 2019 Jan; 162():32-50. PubMed ID: 30408747
[TBL] [Abstract][Full Text] [Related]
32. Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses.
Galindo I; Garaigorta U; Lasala F; Cuesta-Geijo MA; Bueno P; Gil C; Delgado R; Gastaminza P; Alonso C
Antiviral Res; 2021 Feb; 186():104990. PubMed ID: 33249093
[TBL] [Abstract][Full Text] [Related]
33. Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.
Morales-Tenorio M; Ginex T; Cuesta-Geijo MÁ; Campillo NE; Muñoz-Fontela C; Alonso C; Delgado R; Gil C
Eur J Med Chem; 2021 Nov; 223():113654. PubMed ID: 34175537
[TBL] [Abstract][Full Text] [Related]
34. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.
Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Mandelkern T; Zheng M; Xu T; Rothberg J; Lichenstein H
Blood; 2017 Mar; 129(13):1768-1778. PubMed ID: 28104689
[TBL] [Abstract][Full Text] [Related]
35. Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor.
Cheng H; Schafer A; Soloveva V; Gharaibeh D; Kenny T; Retterer C; Zamani R; Bavari S; Peet NP; Rong L
Antiviral Res; 2017 Sep; 145():24-32. PubMed ID: 28645623
[TBL] [Abstract][Full Text] [Related]
36. Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing.
Shrivastava-Ranjan P; Flint M; Bergeron É; McElroy AK; Chatterjee P; Albariño CG; Nichol ST; Spiropoulou CF
mBio; 2018 May; 9(3):. PubMed ID: 29717011
[TBL] [Abstract][Full Text] [Related]
37. Induction of Cell-Cell Fusion by Ebola Virus Glycoprotein: Low pH Is Not a Trigger.
Markosyan RM; Miao C; Zheng YM; Melikyan GB; Liu SL; Cohen FS
PLoS Pathog; 2016 Jan; 12(1):e1005373. PubMed ID: 26730950
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Ebola virus entry by a C-peptide targeted to endosomes.
Miller EH; Harrison JS; Radoshitzky SR; Higgins CD; Chi X; Dong L; Kuhn JH; Bavari S; Lai JR; Chandran K
J Biol Chem; 2011 May; 286(18):15854-61. PubMed ID: 21454542
[TBL] [Abstract][Full Text] [Related]
39. Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway.
Spence JS; Krause TB; Mittler E; Jangra RK; Chandran K
mBio; 2016 Feb; 7(1):e01857-15. PubMed ID: 26861015
[TBL] [Abstract][Full Text] [Related]
40. Snx10 and PIKfyve are required for lysosome formation in osteoclasts.
Sultana F; Morse LR; Picotto G; Liu W; Jha PK; Odgren PR; Battaglino RA
J Cell Biochem; 2020 Apr; 121(4):2927-2937. PubMed ID: 31692073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
